MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

α-synuclein antibody 5G4 identifies manifest and prodromal Parkinson’s disease in colonic mucosa

M. Skorvanek, E. Gelpi, E. Mechirova, Z. Ladomirjakova, V. Han, N. Lesko, E. Feketeova, J. Ribeiro Ventosa, F. Kudela, K. Kulcsarova, S. Babinska, S. Toth, L. Gombosova, F. Trebuna, M. Lutz, Z. Gdovinova, G. Kovacs (Kosice, Slovakia)

Meeting: 2018 International Congress

Abstract Number: 1753

Keywords: Alpha-synuclein, Parkinsonism

Session Information

Date: Monday, October 8, 2018

Session Title: Parkinson's Disease: Pathophysiology

Session Time: 1:15pm-2:45pm

Location: Hall 3FG

Objective: The aim of this study was to evaluate colonic mucosa staining using the 5G4 antibody, specific only for the disease-associated form of α-synuclein, in a deeply phenotyped cohort of clinically manifest PD patients, patients meeting MDS research criteria for prodromal PD (pPD), and healthy controls (HC) not meeting the prodromal PD criteria.

Background: Previous studies point to a potential role of peripheral tissue biopsies as potential biomarkers of PD including its prodromal stages. Recently, a monoclonal α-synuclein antibody (clone 5G4) has been reported to show high reactivity for disease-associated forms, including oligomers, of α-synuclein, with superior results in comparative immunohistochemical studies in the CNS.1

Methods: Patients undergoing diagnostic colonoscopies were screened for all risk and prodromal markers from the MDS research criteria for prodromal PD, except genetic testing and PET/SPECT studies. Immunoreactivity for 5G4 antibody was performed in formalin-fixed in vivo biopsy samples of the colonic mucosa of patients with manifest PD (n=6), pPD (n=7) and HCs (n=17) and were evaluated by two experienced independent and blinded raters.

Results: Pathological 5G4 positive neuritic structures were present in 5/6 clinically manifest PD patients, 4/7 pPD subjects and 2/17 HCs, yielding sensitivity 83.3%, specificity 88.2%, positive predictive value 71.43% and negative predictive value 93.75% for distinguishing manifest PD from healthy controls; and sensitivity 57.1%, specificity 88.2%, positive predictive value 66.7% and negative predictive value 83.3% for distinguishing probable pPD subjects from HCs. Both HCs with positive 5G4 immunostaining reported previous frequent pesticide exposure, while one of them had also constipation, hyposmia and increased MDS-UPDRS part III score, however, she did not exceed the threshold for probable prodromal PD.

Conclusions: 5G4 immunoreactivity in colonic mucosa is able to distinguish clinically manifest and prodromal PD patients from healthy controls. Although these results need to be confirmed in independent and larger cohorts, our study suggests a predictive value of diagnostic colon biopsies containing mucosal tissue with nerve structures.

References: 1. Kovacs GG, Wagner U, Dumont B, et al. An antibody with high reactivity for disease-associated α-synuclein, reveals extensive brain pathology. Acta Neuropathol 2012; 124: 37-50.

To cite this abstract in AMA style:

M. Skorvanek, E. Gelpi, E. Mechirova, Z. Ladomirjakova, V. Han, N. Lesko, E. Feketeova, J. Ribeiro Ventosa, F. Kudela, K. Kulcsarova, S. Babinska, S. Toth, L. Gombosova, F. Trebuna, M. Lutz, Z. Gdovinova, G. Kovacs. α-synuclein antibody 5G4 identifies manifest and prodromal Parkinson’s disease in colonic mucosa [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/%ce%b1-synuclein-antibody-5g4-identifies-manifest-and-prodromal-parkinsons-disease-in-colonic-mucosa/. Accessed May 9, 2025.
  • Tweet
  • Email
  • Print

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/%ce%b1-synuclein-antibody-5g4-identifies-manifest-and-prodromal-parkinsons-disease-in-colonic-mucosa/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley